Stevanato Group Earnings Call Transcripts
Fiscal Year 2026
-
The company is accelerating its shift to high-value, ready-to-fill products, investing heavily in capacity and innovation to serve the growing biologics and GLP-1 markets. Revenue and margins are rising, with a target of 30% EBITDA in 12-24 months, driven by strong demand for advanced syringes and cartridges.
-
With a 75-year legacy, the company has achieved double-digit growth by focusing on high-value pharmaceutical packaging and drug delivery systems. Major investments in global capacity and R&D support leadership in biologics and GLP-1, with high-value products now nearly half of revenue.
-
Strong growth in high-value solutions, especially for biologics and GLP-1s, is driving revenue and margin expansion. Major capacity investments in the U.S. and Italy are nearly complete, supporting future growth and improved cash flow. Adjusted EBITDA margin is on track to reach 30% by 2027.
-
Q1 2026 saw 10% constant currency revenue growth, led by high-value solutions and strong BDS segment performance, while engineering margins improved despite lower revenue. Guidance for 2026 is maintained, with robust demand for cartridges and biologics, and ongoing investments in capacity expansion.
-
Strong growth in high-value solutions and biologics drove margin expansion and record revenues in 2025, with further gains expected in 2026. Major capacity investments in sterile cartridges and drug delivery systems support long-term growth, while new plants are set to deliver high profitability.
Fiscal Year 2025
-
Fiscal 2025 saw strong revenue and margin growth, led by high-value solutions and robust GLP-1 demand. 2026 guidance anticipates continued BDS growth, margin expansion, and high-value solutions reaching up to 48% of revenue, despite currency and engineering headwinds.
-
The company is leveraging its global leadership in injection-related products to drive growth through high-value solutions, robust investments, and deep integration with pharma clients. Demand is strong in biologics and GLP-1 therapies, with biosimilars and engineering optimizations supporting future expansion.
-
Major CapEx investments and a shift to high-value products are driving growth, especially in biologics and GLP-1s. Policy clarity and reshoring support future U.S. expansion, while engineering segment efficiency is improving despite order timing delays.
-
Q3 revenue grew 9% year-over-year, led by high-value solutions and strong BDS segment growth. Margins expanded, guidance for 2025 was reiterated, and capacity investments continue to support robust demand in biologics and ready-to-use products.
-
The company is executing a global expansion focused on high-value solutions, with major investments in new manufacturing sites and strong multi-year customer partnerships. Financial performance is robust, driven by margin expansion and growth in high-value products, while operational improvements and market trends in biologics and drug delivery systems support a positive outlook.
-
Capacity expansion in Italy and the U.S. is on track, supported by long-term contracts and a focus on high-value products with strong gross margins. Biologics and GLP-1s drive growth, while inventory normalization and engineering improvements support future profitability. Fishers and Latina facilities are key to long-term revenue and margin expansion.
-
Q2 2025 saw 8% revenue growth, margin expansion, and strong BDS segment performance, offsetting engineering declines. High-value solutions rose to 42% of revenue, and guidance for 2025 is reiterated, with ongoing investments and market tailwinds supporting long-term growth.
-
The company is experiencing strong growth in biologics and injectables, with major capacity expansions in the U.S. and Italy supporting double-digit growth targets. Proprietary device innovation and robust demand are driving revenue, while risk management and operational optimization ensure resilience.
-
With a 75-year legacy, the group has doubled revenue in five years and is investing over EUR 1 billion to expand global capacity, focusing on high-value products for biologics and injectables. Q1 2024 showed 9% growth, and major investments are now contributing to revenue.
-
Q1 2025 saw 9% revenue growth and margin expansion, led by strong BDS segment performance and high-value solutions. Guidance for FY 2025 is reiterated, with tariff impacts largely mitigated and robust demand expected to drive sequential improvement in revenue and margins throughout the year.
-
U.S. listing enabled benchmarking and growth, with a focus on pharma and integrated solutions. Major expansions in Indiana and Latina are progressing, driven by strong demand and multi-year contracts. High-value products and biologics are key growth areas, while operational improvements and market normalization are underway.
-
Management highlighted strong fundamentals, global expansion, and a focus on high-value solutions, with capacity investments and regulatory trends supporting future growth. Vial demand is recovering, and the company expects a return to double-digit growth and higher margins by 2027.
Fiscal Year 2024
-
Revenue grew 2% in 2024, led by high-value syringes and biologics, while vial demand declined but is recovering. 2025 guidance anticipates stronger growth in the second half, margin improvement, and continued investment in capacity expansion.
-
Destocking is progressing unevenly, with normalization expected by the end of 2025. High-value solutions are driving growth, and facility expansions in Latina and Fishers are on track to boost capacity and margins. Long-term plans target double-digit growth and higher margins by 2027.
-
Management outlined a path to double-digit revenue growth and 30% EBITDA by 2027, supported by robust biologics demand, capacity expansions, and a shift toward high-value products. Vial destocking is expected to normalize by 2025, with strong recovery in syringes and cartridges.
-
Q3 saw growth in high-value products despite vial destocking, with new plant investments progressing and long-term contracts supporting future revenue. Engineering division restructuring aims to restore margins, while regulatory and therapeutic trends drive demand for advanced solutions. 2027 targets for margin and high-value mix are reaffirmed.
-
Q3 2024 saw modest revenue growth driven by high-value solutions, but margins were pressured by higher costs in engineering and new facility ramp-ups. Guidance for Adjusted EBITDA and EPS was lowered, while revenue guidance was maintained. Vial destocking continues to weigh on results, but gradual recovery is expected in 2025.
-
Strong growth in high-value syringes and cartridges is offsetting a temporary slowdown in vials, with recovery in major markets expected by 2025. Engineering challenges are being addressed, and margin improvements are anticipated as the product mix shifts to higher-value solutions. CapEx is set to normalize by 2027.
-
Leadership is focused on executing the industrial plan, with major investments in biologics and high-value solutions driving growth. Syringe demand offsets vial destocking, while engineering and new facilities are ramping up. Cautious optimism remains for 2025, with medium-term double-digit growth and margin targets supported by ongoing innovation and global expansion plans.
-
Q2 2024 revenue rose 2% year-over-year, led by strong BDS growth, but margins were pressured by engineering delays and ramp-up inefficiencies. Fiscal 2024 guidance was revised lower due to engineering headwinds, while high-value solutions and biologics remain key growth drivers.
-
A global leader in drug containment and delivery, the group is expanding capacity in the US and Europe to meet rising demand for high-value solutions, especially in biologics. Despite temporary market softness from vial destocking, high-margin products and innovation are driving growth.
-
Steady double-digit growth and leadership in high-value drug containment and delivery solutions position the company to capitalize on rising demand in biologics and advanced therapies. Major investments in U.S. and Italy support capacity expansion, with a focus on execution and margin growth in 2024.